Hanmi Pharmaceutical (128940.KS) unveiled a blueprint to more than double its annual consolidated revenue to 3.5 trillion won ($2.5 billion) by 2030, compared to last year's figures. The broader Hanmi Group aims to achieve 5 trillion won in revenue within five years.
The strategy centers on discovering at least one blockbuster new drug or product annually and differentiating its marketing approach in chronic disease treatments. The company also plans to maintain shareholder returns at 20% or higher each year to enhance shareholder value.
Hanmi Group announced these plans at its "Hanmi Vision Day" event for institutional investors on Friday. This marks the first time the group has disclosed mid- to long-term growth targets since concluding its management control dispute. The event presented a new vision for research and development and shareholder value enhancement, areas that had stalled during the dispute. Kim Jae-kyo, vice chairman of Hanmi Science, Park Jae-hyun, president of Hanmi Pharmaceutical, and other professional managers attended, along with Lim Ju-hyun, vice chairman of Hanmi Group.
Hanmi Pharmaceutical projects consolidated revenue of 1.5 trillion won for this year and aims to achieve average annual revenue growth of 20% or higher through 2030 to reach 3.5 trillion won. During this period, the company also plans to raise its operating profit margin to above 20% to secure both growth and profitability.
The company also presented its value-up plan, which includes introducing a minimum dividend system, conducting share buybacks, and implementing a restricted stock unit program for employees. Through these measures, the company aims to maintain total shareholder returns at a minimum of 20% annually.
Hanmi Pharmaceutical expressed its ambition to grow into a global top pharmaceutical company based on two pillars: fundamental growth and innovative growth. For fundamental growth, the company will pursue evidence-based differentiated marketing in chronic disease treatments and discover at least one blockbuster new drug or product with annual sales exceeding 10 billion won each year.
Starting with Amoprel, the world's first one-third low-dose antihypertensive launched this year, the company plans to develop flagship products including Efpeglenatide, a GLP-1 class obesity treatment that would be the first from a Korean pharmaceutical company, and Rolontis Autoinjector. The company will also strengthen R&D targeting global markets and focus on developing customized new products. Through smart innovation, it plans to elevate its production facilities to global standards.
The company also disclosed its innovative growth strategy for securing future growth drivers. Key elements include actively utilizing open innovation to adopt promising external technologies, pursuing research into various modalities to lead next-generation treatment paradigms, and innovating its R&D environment based on artificial intelligence and bioinformatics technologies.
"We will steadfastly pursue our R&D-centered long-term growth strategy toward 2030, expanding beyond cancer and obesity into anti-aging and reverse-aging research to become a company that creates substantial change in the global pharmaceutical market with medicines that solve humanity's structural problems," Park said.
